These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31849088)

  • 21. Effect of tumor-infiltrating immune cells (mast cells, neutrophils and lymphocytes) on neoadjuvant chemotherapy response in breast carcinomas.
    Okcu O; Öztürk Ç; Yalçın N; Yalçın AC; Şen B; Aydın E; Öztürk AE
    Ann Diagn Pathol; 2024 Jun; 70():152301. PubMed ID: 38581761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy.
    Asaoka M; Narui K; Suganuma N; Chishima T; Yamada A; Sugae S; Kawai S; Uenaka N; Teraoka S; Miyahara K; Kawate T; Sato E; Nagao T; Matsubara Y; Gandhi S; Takabe K; Ishikawa T
    Eur J Surg Oncol; 2019 Dec; 45(12):2289-2294. PubMed ID: 31787153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
    Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer by combining magnetic resonance imaging and core needle biopsy.
    Narui K; Ishikawa T; Oba MS; Hasegawa Y; Kaise H; Kawate T; Yamada A; Yamada K; Suzuki Y; Niikura N; Kohno N; Kimoto T; Sugae S; Kosaka Y; Miyashita M; Okamura T; Shimizu D; Tanino H; Tanabe M; Morita S; Endo I; Tokuda Y
    Surg Oncol; 2020 Dec; 35():447-452. PubMed ID: 33045629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
    Li XB; Krishnamurti U; Bhattarai S; Klimov S; Reid MD; O'Regan R; Aneja R
    Am J Clin Pathol; 2016 Jun; 145(6):871-8. PubMed ID: 27298399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.
    Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Noda S; Takashima T; Onoda N; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    BMC Cancer; 2017 Dec; 17(1):888. PubMed ID: 29282021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses.
    Yang Y; Im SA; Keam B; Lee KH; Kim TY; Suh KJ; Ryu HS; Moon HG; Han SW; Oh DY; Han W; Kim TY; Park IA; Noh DY
    BMC Cancer; 2016 Jul; 16():515. PubMed ID: 27444430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
    Dieci MV; Frassoldati A; Generali D; Bisagni G; Piacentini F; Cavanna L; Cagossi K; Puglisi F; Michelotti A; Berardi R; Banna G; Goubar A; Ficarra G; Griguolo G; Conte P; Guarneri V
    Breast Cancer Res Treat; 2017 Jun; 163(2):295-302. PubMed ID: 28289852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
    Hwang HW; Jung H; Hyeon J; Park YH; Ahn JS; Im YH; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Choi M; Cho SY; Cho EY
    Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter.
    Piotrzkowska-Wróblewska H; Dobruch-Sobczak K; Klimonda Z; Karwat P; Roszkowska-Purska K; Gumowska M; Litniewski J
    PLoS One; 2019; 14(3):e0213749. PubMed ID: 30870478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Residual Pure Intralymphatic Breast Carcinoma Following Neoadjuvant Chemotherapy Is Indicative of Poor Clinical Outcome, Even in Node-Negative Patients.
    Cheng E; Ko D; Nguyen M; Moo TA; Andreopoulou E; Hoda SA; D'Alfonso TM
    Am J Surg Pathol; 2017 Sep; 41(9):1275-1282. PubMed ID: 28654428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer.
    Erol VB; Goktas Aydin S; Bilici A; Cakir A; Acikgoz O; Olmez OF; Basim P
    J Chemother; 2023 Nov; 35(7):662-670. PubMed ID: 37599454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to immunohistochemical markers' conversion after neoadjuvant chemotherapy in breast cancer patients: association between imaging and histopathologic analysis.
    Zhao Y; Wang X; Huang Y; Zhou X; Zhang D
    Clin Transl Oncol; 2020 Jan; 22(1):91-102. PubMed ID: 31006089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.